SHAMPOO:
The current formulation of active ingredients used for the production of anti-dandruff shampoos constitute many hazardous chemicals with long lasting toxic characteristics. Therefore, new approaches especially those that capitalize on the unique antibacterial properties of nanoparticles are being explored by various anti-dandruff manufacturing corporations. NBI’s proprietary silver nanotechnology has been recently tested for anti-dandruff properties. The results are compelling because the anti-dandruff features achieved using NBI’s silver nanotechnology exceeds industry standards and also the silver nanoparticles have demonstrated no systemic/dermal toxicity. NBI’s silver nanotechnology has already been scaled up for the production of specific types of silver nanoconstructs for use in large scale manufacture of anti-dandruff shampoos. These results have prompted FMCG industry organizations to seek NBI’s nanotechnology formulations for use in anti-dandruff shampoos, antibacterial soaps and related antibacterial consumer products.
NANOSILVER PRODUCTS:
The strongest growth for silver nanoparticle-based biocides is currently coming from the medical and healthcare industries and in hygienic surface applications. In particular, antimicrobial sprays for hospitals for controling sperad of bacteria and virus, plastics as part of the solution to healthcare-acquired infections. In minute concentrations, silver is highly toxic to germs while relatively non-toxic to human cells.
IMAGING AGENTS:
Molecular imaging involves integration of new imaging probes and imaging agents with existing or new imaging technology to achieve more accurate and precise in vivo detection of lesions and other, disorders in specific organs in animal and human systems. The ability of nanoparticles to target individual cells, or for targeted nanoparticles to home into tumors through receptor mediated biomolecular interactions, is altering the landscape of traditional imaging instruments makers. NBI is one of the few companies in the world with proprietary technologies for the development of cancer specific gold nanoparticles. NBI's scientists have developed a peptide conjugate, AuNP-BBN, which selectively targets prostate, breast and small cell lung cancer. AuNP-BBN has already shown efficacy for its use in enhancing contrasts in CT imaging using in vivo animal models. NBI is already marketing over 150 different types of nanoconstructs serving technology, medical, environmental industry and research clients worldwide. The current network of clients is expected to grow substantially with the launch of AuNP-BBN in the market. The National Institutes of Health has already included AuNP-BBN in its data base of tumor specific nanoparticluate agents.
THERAPY AGENTS:
Radiation therapy utilizes ionizing radiation to shrink tumors. An ideal radiotherapeutic agent should have high tumor shrinking efficacy, low leakage of radioactivity to non-tumoral regions, and should be easily implantable or injectable. Radiation to solid tumors are usually delivered by placing the radioactivity closer to or inside the tumor (brachy therapy) or via unsealed radioactive materials injected in the body (systemic radiotherapy). One of the major limitations with current clinical brachy therapy is the leakage of radioactive materials to non-target regions. Administration of the inherently heterogeneous brachy seeds is also a major impediment as documented by oncologists. In this context, NBI has developed readily injectable, nanosized homogeneous gold particles embedded in a gum Arabic matrix which has established high tumor shrinking and retention capabilities. NBI’s GA-AuNP would be the first injectable brachy agent for use in the treatment of a variety of human tumors.
|
